Why This Study Matters
Electroconvulsive therapy (ECT) and intravenous (IV) ketamine are both powerful options for people with major depressive episodes, especially those who haven’t responded to other treatments. But which one is more effective? A new study sheds light on this question by directly comparing the two treatments in real-world clinical settings.
Inside the Study
Researchers analyzed medical records of 146 adults (ages 18 to 74) who were receiving treatment for major depression. Of these, 94 patients received subanesthetic doses of IV ketamine twice a week, while 52 underwent ECT two to three times weekly. The study lasted three weeks and took place in a psychiatric hospital.
The primary tool used to track symptom changes was the Montgomery-Åsberg Depression Rating Scale (MADRS), a standard measure for evaluating depression severity.
Key Findings: ECT Had Greater Impact
Both ECT and ketamine led to improvements, but ECT stood out:
- Symptom Change: 45.2% of all participants showed measurable improvements by the end of treatment.
- Statistical Significance: Using a Reliable Change Index, 58.9% had significant improvement—especially those receiving ECT.
- Response Rates: ECT had a 67.3% response rate, compared to 45.7% for ketamine.
- Remission Rates: 60.0% of ECT patients reached remission, while 46.1% of ketamine patients did.
These numbers suggest that ECT may be more effective in reducing depressive symptoms, at least in a short-term hospital setting.
ECT vs Ketamine for Depression: How Do They Differ?
ECT uses electrical stimulation to trigger brief seizures in the brain. It has long been used for severe or treatment-resistant depression and is often viewed as a last-resort option due to concerns about memory loss or stigma.
IV ketamine, on the other hand, is a newer approach that targets the brain’s glutamate system. It’s fast-acting, sometimes providing relief within hours, and is often used when rapid improvement is needed.
What This Means for Patients and Providers
For individuals struggling with severe depression, especially those who have tried multiple medications without success, these findings offer important guidance. While ketamine remains a promising option—especially due to its rapid action—ECT may offer deeper, more consistent relief over time. However, more randomized trials are needed to confirm these results.
Conclusion
Both treatments offer hope, but ECT currently shows stronger outcomes in this comparison. As interventional psychiatry evolves, head-to-head studies like this one are crucial in helping providers tailor treatment plans that are both effective and personalized.
Subscribe toIPN to stay update with Interventional Psychiatry.
Citations
- Myerson, J., Rufino, K. A., Mathew, S. J., Fletcher, M., Puri, N., & Oh, H. (2025). Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes. Journal of Affective Disorders, 341, 119727. https://doi.org/10.1016/j.jad.2025.119727
- Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019). Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 101(5), 774–778. https://doi.org/10.1016/j.neuron.2019.02.005